ENSG heads into its July 29 Q2 earnings release with options traders making one of their most bullish bets of the past year.
The options signal is the standout. The put/call ratio collapsed to 0.16 on July 27 — more than two standard deviations below its 20-day average of 0.59, and near the lowest reading in the past 52 weeks. That means call volume is dominating by a wide margin, a posture that reflects conviction rather than caution going into the print. The stock has earned that optimism on price: ENSG has climbed 9.2% over the past month to $178.07, adding another 3.5% on the week.
The lending market adds no friction to that bullish read. Availability is extraordinarily loose — over 4,000% of short interest is covered by available borrow, meaning there are roughly 42 shares available for every one already lent out. Cost to borrow is just 0.33%, down 8% on the week and 21% over the past month. Short interest ticked up 11% on the week to 3.7% of the free float, but that's still modest in absolute terms and sits well below mid-June peaks around 4.9%. The borrow market poses no squeeze threat; the uptick in shorts looks like tactical positioning, not a structural bear thesis building.
The debate between bulls and bears centres on execution at scale. The bull case rests on Ensign's decentralised model, its consistent acquisition cadence, and guidance that already beat consensus for 2026. Bears point to a 1.77x adjusted net debt/EBITDA ratio and the persistent risk of reimbursement pressure from Medicare and Medicaid — genuine constraints in a post-acute care environment that remains competitive. The Street leans bullish overall, with a consensus target near $219 implying roughly 23% upside from current levels. The most recent analyst action, from Truist Securities in mid-July, trimmed its target from $215 to $202 while keeping a Hold — a signal that at least one firm sees the recent rally as having priced in much of the near-term upside. RBC Capital and UBS both carry positive ratings with targets above $220.
The past three earnings prints left a pattern worth noting: ENSG declined on each occasion, with five-day losses ranging from 3% to 8%. The Q2 report will test whether this quarter's operational momentum and M&A progress — and the unusually aggressive call positioning ahead of it — can break that streak.
See the live data behind this article on ORTEX.
Open ENSG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
